A carregar...
No augmentation of indoleamine 2,3‐dioxygenase (IDO) activity through belatacept treatment in liver transplant recipients
Belatacept is a second‐generation cytotoxic T lymphocyte antigen (CTLA)‐4 immunoglobulin (Ig) fusion protein approved for immunosuppression in renal transplant recipients. It was designed intentionally to interrupt co‐stimulation via CD28 by binding to its ligands B7·1 and B7·2. Experimental evidenc...
Na minha lista:
| Publicado no: | Clin Exp Immunol |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5904696/ https://ncbi.nlm.nih.gov/pubmed/29271486 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13093 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|